2Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma [ J ]. J Natl Cancer Inst ,2008, 100(10) :698 - 711.
3Chio H, Charnsangarzj C, Silvana C, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal with imatinib mestlate : proposal of new computed tomography response criteria[ J]. JCO, 2007,25 ( 13 ) : 1753 - 1759.
4Bang Y, Kang Y, Kang W, et al. Sunitinib as second-line treatment for advanced gastric cancer:preliminary results from a phase II study[J]. JCO, 2007: a4603.
2Mazur MT, Clark HB. Gatric stromal tumors: reappraisal of histogenesis [ J ]. Am J Surg Pathol, 1983,7 ( 16 ) :507 - 519.
3Therasse P, Arbuck SG, Eisenhauer EA ,et al. New guidelines to evalute the response to treatment in solid tumors [ J ]. J Natl Cancer Inst ,2000,92:205 - 206.
4Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumors [ J ]. Curr Oncol Rep, 2005,7(4) :307 -311.
5Choi H. Response evaluation of gastrointestinal stromal tumors [J]. Oncologist, 2008, 13(Snppl 2) :4 -7.
6Miettinen M, Lasota J. Gastrointestinal stromal tumors. Virchows Arch, 2001, 438(1):1 -12.
7Choi H, Charnsangavej C, Faria SC, et al, Correlation of computed tomography and positron emmision tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria[ J ]. J Clin Oncol,2007, 25 (13) : 1753 - 1759.
8Benjamin RS,Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST[J]. J Clin Oncol, 2007, 25: 1760 - 1764.
9Bulusu VR, Jephcott CR, Fawcett S, et al. RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate[ C]. Proceeding of ASCO, 2007 : a10019.
10Bulusu VR, Fawcett S, Moyle P, et al. Interobserver variability of size and density measurements on CT in patients with metastatic GISTS on imatinib mesylate (IM) [ C ]. Proceeding of ASCO, 2008:a10563.
3Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248[J]. Mol Cancer Ther,2006, 5(5): 1280-1289.
4The whoqol group. Development of the world health organization WHOQOL-BREF quality of life assessment[J]. Psychological Medicine, 1998, 28,551-558.
